Levels of Adipokines–Adiponectin and Resistin in Patients with Metabolic Syndrome and Newly Diagnosed Diabetes Mellitus Type 2

It has been recently proven, that the adipose tissue is not just a passive energy depot, but rather active endocrine organ – adipocytes are expressing on their surface multiple receptors and are releasing adipokines, hormones, cytokines, growth factors. Aim of the present study was to examine the serum levels of adipokines – adiponectin and resistin in patients with metabolic syndrome (MS) and newly diagnosed diabetes mellitus type 2 (NDDMt2). A prospective, comparative, observational study was performed. In 45 subjects with MS and NDDMt2 (n₁=45) and 35 clinical health subjects (n₂=35) were measured and compared the serum levels of adipokines – adiponectin and resistin. Two homoeostasis models assessment of insulin resistance (HOMA-IR) and of β-cell function (HOMA-%В) were calculated. A significantly lower level of adiponectin was detected in patients with MS and NDDMt2 in comparison whit the control group (n₁=0.97±0.47 vs. n₂=1.96±0.73 μg/ml; p=0.005). A significantly higher level of resistin was found in patients with MS and NDDMt2 in comparison whit controls (n₁=1.85±0.70 vs. n₂=0.71±0.31 ng/ml; p=0.025). We have found negative correlations between concentration of adiponectin and serum levels of resistin, BMI and waist circumference in MS and NDDMt2 patients. The resistin was positively correlated with BMI and waist circumference, and was negatively correlated with HDL-cholesterol in MS and NDDMt2 patients.Patients with MS and NDDMt2 exhibited significantly changes in levels of adiponectin and resistin. Indicated adipokines may have predictive value of progression from normal to pathological carbohydrate metabolism.